These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24557073)

  • 21. Forced degradation studies of biopharmaceuticals: Selection of stress conditions.
    Tamizi E; Jouyban A
    Eur J Pharm Biopharm; 2016 Jan; 98():26-46. PubMed ID: 26542454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biopharmaceutical study of para-aminosalicyclic acid tablets].
    Bustos D; Cid E
    Farmaco Prat; 1975 Aug; 30(8):388-97. PubMed ID: 1157916
    [No Abstract]   [Full Text] [Related]  

  • 23. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP40101M.
    Krishna G; Hodnick WF; Lang W; Lin X; Karra S; Mao J; Almassian B
    AAPS PharmSciTech; 2001 Aug; 2(3):E14. PubMed ID: 14727873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formulation and manufacturability of biologics.
    Shire SJ
    Curr Opin Biotechnol; 2009 Dec; 20(6):708-14. PubMed ID: 19880308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Partitioning phenomena in dosage form and biopharmaceutical design. II. Some partitioning considerations in dosage form design.
    Schumacher GE
    Am J Hosp Pharm; 1971 Dec; 28(12):985-8. PubMed ID: 5135196
    [No Abstract]   [Full Text] [Related]  

  • 27. HPMC as a potential enhancer of nimodipine biopharmaceutical properties via ball-milled solid dispersions.
    Riekes MK; Kuminek G; Rauber GS; de Campos CE; Bortoluzzi AJ; Stulzer HK
    Carbohydr Polym; 2014 Jan; 99():474-82. PubMed ID: 24274533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mixed lipid phase SMEDDS as an innovative approach to enhance resveratrol solubility.
    Bolko K; Zvonar A; Gašperlin M
    Drug Dev Ind Pharm; 2014 Jan; 40(1):102-9. PubMed ID: 23301796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin-like growth factor-I aerosol formulations for pulmonary delivery.
    Germershaus O; Schultz I; Lühmann T; Beck-Broichsitter M; Högger P; Meinel L
    Eur J Pharm Biopharm; 2013 Sep; 85(1):61-8. PubMed ID: 23958318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative biopharmaceutical study of tegalide].
    Lopatina NB; Lebedeva MN
    Med Parazitol (Mosk); 2000; (1):27-9. PubMed ID: 10808715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proceedings: In vitro:in vivo correlation and ageing studies of commercial hydrochlorothiazide tablets.
    Hossie RD; Mattok GL; McGilveray IJ
    Rev Can Biol; 1973; 32():85-9. PubMed ID: 4777590
    [No Abstract]   [Full Text] [Related]  

  • 32. Development of an in vitro/in vivo correlation for lipid formulations of EMD 50733, a poorly soluble, lipophilic drug substance.
    Schamp K; Schreder SA; Dressman J
    Eur J Pharm Biopharm; 2006 Apr; 62(3):227-34. PubMed ID: 16246538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro evaluation of extemporaneously compounded immediate-release capsules with premixed excipients, based on the biopharmaceutics classification system (BCS) of the drugs.
    Pinheiro VA; Danopoulos P; Demirdjian L; Nogueira RJ; Dubois F
    Int J Pharm Compd; 2013; 17(5):424-31. PubMed ID: 24459788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of the stability and handling of recombinant protein drugs.
    Geigert J
    J Parenter Sci Technol; 1989; 43(5):220-4. PubMed ID: 2809930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro/in vivo characterization of nanocrystalline formulation of tranilast with improved dissolution and hepatoprotective properties.
    Onoue S; Yamamoto K; Kawabata Y; Yamada S
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):952-7. PubMed ID: 24055688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
    Prabhu S; Ortega M; Ma C
    Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parenteral formulation of larotaxel lipid microsphere tackling poor solubility and chemical instability.
    Teng F; Yang H; Li G; Lin X; Zhang Y; Tang X
    Int J Pharm; 2014 Jan; 460(1-2):212-9. PubMed ID: 24184034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein drug stability: a formulation challenge.
    Frokjaer S; Otzen DE
    Nat Rev Drug Discov; 2005 Apr; 4(4):298-306. PubMed ID: 15803194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.
    Jorgensen L; Hostrup S; Moeller EH; Grohganz H
    Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.